

Original

Lipopolysaccharide-Treated Human Gingival Fibroblasts Continuously Produce PGE₂

Toshiaki Ara^{1,2}, Yoshiaki Fujinami¹, Yasuhiro Imamura^{1,2} and Pao-Li Wang^{1,2}

¹Department of Pharmacology, Matsumoto Dental University, 1780 Gobara, Hirooka, Shiojiri, Nagano 399-0781, Japan

²Department of Hard Tissue Research, Graduate School of Oral Medicine, Matsumoto Dental University, 1780 Gobara, Hirooka, Shiojiri, Nagano 399-0781, Japan

(Accepted for publication, October 20, 2008)

Abstract: The aim of this study was to examine whether human gingival fibroblasts (HGFs) sustain to produce prostaglandin E₂ (PGE₂) in the presence of lipopolysaccharide (LPS). HGFs were treated with or without 10 ng/ml of LPS from *Porphyromonas gingivalis* (PgLPS) for 7 days collecting the culture supernatants for every 24 h, and PGE₂ concentration in the supernatants was measured by ELISA. HGFs produced PGE₂ at low level without PgLPS treatment. In contrast, HGFs continuously produce PGE₂ with PgLPS treatment. At each day, the amount of PGE₂ production by HGFs with PgLPS treatment was higher than that without treatment. These results demonstrate that the characteristic of HGFs, which continuously produce PGE₂ in the presence of LPS, sustains inflammatory response in periodontal disease.

Key words: Human gingival fibroblast, Lipopolysaccharide, Prostaglandin E₂

Introduction

Caries and periodontal disease are two major oral diseases and both are considered to be infections caused by biofilms^{1,2}. In particular, periodontal disease is highly prevalent and can affect most of the world population. Periodontal disease is accompanied by inflammation of the gingiva and destruction of periodontal tissues, leading to alveolar bone loss in severe clinical cases. *Porphyromonas gingivalis* (*P. gingivalis*), a gram-negative bacterial species with black pigmentation, is one of the suspected periodontopathic bacteria and is frequently isolated from the periodontal pockets of patients with chronic periodontal disease^{3,4}. Periodontopathic bacteria produce many virulence factors such as lipopolysaccharide (LPS) and peptidoglycan, and these bacterial factors induce host responses including the production of pro-inflammatory cytokines and prostaglandin E₂ (PGE₂). In particular, because PGE₂ has several functions in vasodilation and the enhancement of vascular permeability and pain, the induction of osteoclastogenesis, PGE₂ plays an important role in inflammatory response and alveolar bone resorption in periodontal disease⁵.

IL-6, IL-8 and PGE₂ are produced by not only inflammatory cells (monocyte and macrophage) but also human gingival fibroblasts (HGFs)⁶⁻⁹. Among these cells, we assume that HGFs are the most important cells that produce inflammatory cytokines

and PGE₂ because HGFs are the most prominent cells in periodontal tissue.

It has been well documented that the LPS-induced production of inflammatory cytokines was down-regulated by LPS-pretreatment in inflammatory cells such as peripheral blood mononuclear cells^{10,11}, monocytes^{12,13} and macrophages^{14,15}. Moreover, LPS-induced PGE₂ production was also down-regulated in macrophage-like cells¹⁶. Recently, we reported that HGFs sustain to produce IL-6 and IL-8 in the presence of LPS¹⁷. However, it remains elucidated that whether HGFs sustain to produce PGE₂ production. Therefore, to investigate whether HGFs sustain to produce PGE₂ in the presence of LPS is of interest in the viewpoint of the pathology of periodontal disease. To reveal to this point, we examined PGE₂ production by HGFs treated with LPS continuously.

Materials and methods

Reagents and cells

LPS from *P. gingivalis* 381 (PgLPS) was provided by Drs. Tatsuji Nishihara and Nobuhiro Hanada (National Institutes of Public Health, Wako, Japan). HGFs were prepared as described previously^{18,19}. HGFs were maintained in Dulbecco's modified Eagle's medium (D-MEM; Sigma) containing 10% heat-inactivated fetal calf serum (FCS), 100 units/ml penicillin and 100 mg/ml streptomycin, at 37°C in a humidified atmosphere of 5% CO₂. This study was approved by the Ethical Committee of

Correspondence to: Dr. Pao-Li Wang, Department of Pharmacology, Matsumoto Dental University, 1780 Gobara, Hirooka, Shiojiri, Nagano 399-0781, Japan. Phone& FAX: 81-263-51-2102. E-mail address: ohhourei@po.mdu.ac.jp

our institution. Informed consent was obtained from each subject for the collection of HGFs.

Cytokine measurement

HGFs were seeded in 96-well plates (Asahi Techno Glass Corp., Tokyo, Japan) at 10,000 cells/ml. The next day, HGFs were treated with or without 10 ng/ml of PgLPS (200 µl per each well) for 7 days collecting the culture supernatants for every 24 h (Fig. 1A), and the concentration of PGE₂ was measured by enzyme-linked immunosorbent assay (ELISA) according to the manufacture's instructions (Cayman Chemical, Ann Arbor, MI).

Results

To investigate whether prolonged exposure to LPS affects the production of inflammatory cytokine, HGFs were treated with or without 10 ng/ml of PgLPS for 7 days. HGFs produced basal level of PGE₂ (< 100 pg/ml) at each day without LPS treatment (Fig. 1). When treated with PgLPS, HGFs produced a large amount of PGE₂ (Fig. 1B). At each day, the amount of PGE₂ with LPS treatment is apparently higher than without PgLPS treatment although PGE₂ levels at day 3 or 4 are lower than that at day 1. These results indicate that HGFs sustain to produce PGE₂ after exposure to PgLPS for at least 7 days.




Figure 1. PGE₂ production after prolonged exposure to LPS. (A) HGFs were treated with or without 10 ng/ml of PgLPS for 7 days. For every 24 h, culture supernatants were collected, and cells were washed with PBS and culture medium with PgLPS was added. (B) The level of PGE₂ in culture supernatants at from day 1 to day 7 was measured by ELISA. Results are the mean ± SD of triplicate samples.

Discussion

Until now, many reports have demonstrated that the secondary LPS-induced production of inflammatory cytokines and PGE₂ was

down-regulated by primary LPS in inflammatory cells such as PBMC, monocytes and macrophage (*i.e.* LPS tolerance)¹⁰⁻¹⁶. In this study, we demonstrated that in the presence of LPS, HGFs sustain to produce PGE₂ as well as inflammatory cytokines (IL-6 and IL-8)¹⁷. Because (i) HGFs are the prominent cells in periodontal tissue, (ii) HGFs continuously produce PGE₂ and (iii) macrophages show LPS tolerance¹⁶, we consider that HGFs rather than monocytes/macrophages are the primary cells responsible for the production of PGE₂ in periodontal tissue and that continuous PGE₂ production leads to persisting inflammatory response. This assumption is supported by the previous report that cyclooxygenase (COX)-2 was detected in fibroblasts as well as other cells in inflamed gingiva⁵.

Down-regulation of cell-surface toll-like receptor (TLR)4 expression is one of the LPS tolerance mechanisms²⁰. Moreover, several negative-regulators such as suppressor of cytokine signaling-1 (SOCS-1)^{21,22}, interleukin-1 receptor-associated transducer for interleukin (IRAK)-M²³ and SH2 domain-containing inositol-5-phosphatase (SHIP)-1²⁴ also play important roles in LPS tolerance. SOCS-1 and IRAK-M, especially, inhibit LPS-TLR signaling pathway by suppression of adaptor molecules²⁵, resulting in down-regulation of p38, Jun N-terminal kinase (JNK) and nuclear factor (NF)-κB signaling pathways. These signal pathways, at least in part, are essential to IL-6, IL-8 and COX-2 expressions^{26,27}. However, from the finding that (i) HGFs treated with LPS for 24 h expressed similar level of TLR4 expression compared to without treatment²⁸ and that (ii) LPS-treated HGFs failed to induce SOCS-1 and IRAK-M¹⁷, it is suggested that COX-2 expression and following PGE₂ production are not suppressed in LPS-treated HGFs.

In conclusion, we demonstrated that HGFs sustain to produce PGE₂ in the presence of LPS. From this and our previous findings, we suggest that HGFs are critical in the pathology of periodontal disease. Our findings may provide the basic and clinical evidences that this characteristic of HGFs sustains inflammatory response in the presence of virulence factors and that the elimination of biofilm is essential to the treatment of periodontal disease.

Acknowledgments

We thank Drs. Tatsuji Nishihara and Nobuhiro Hanada for providing *P. gingivalis* LPS. We also thank Associate Prof. Takashi Uematsu (Department of Oral and Maxillofacial Surgery) for HGFs preparation and Keiko Fujii for technical assistance. The study was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports (Code No. 18791390) and Culture of Japan and a Scientific Research Special Grant from Matsumoto Dental University.

References

1. Costerton J W, Stewart P S and Greenberg E P. Bacterial biofilms. a common cause of persistent infections. *Science*

- 284:1318-1322,1999
2. Tamura A, Ara T, Imamura Y, Fujii T and Wang P L. The effects of antibiotics on *in vitro* biofilm model of periodontal disease. *Eur J Med Res* 13: 439-445, 2008
 3. Mouton C, Hammond P G, Slots J and Genco R J. Serum antibodies to oral *Bacteroides asaccharolyticus* (*Bacteroides gingivalis*) relationship to age and periodontal disease. *Infect Immun* 31:182-192, 1981
 4. Holt S C, Ebersole J, Felton J., Brunsvold M and Kornman K S. Implantation of *Bacteroides gingivalis* in nonhuman primates initiates progression of periodontitis. *Science* 239:55-57, 1988
 5. Noguchi K and Ishikawa I. The roles of cyclooxygenase-2 and prostaglandin E₂ in periodontal disease. *Periodontol* 2000 43:85-101, 2007
 6. Bartold P M. and Haynes D R. Interleukin-6 production by human gingival fibroblasts. *J Periodontal Res* 26:339-345, 1991
 7. Tamura M, Tokuda M, Nagaoka S and Takada H. Lipopolysaccharides of *Bacteroides intermedius* (*Prevotella intermedia*) and *Bacteroides* (*Porphyromonas*) *gingivalis* induce interleukin-8 gene expression in human gingival fibroblast cultures. *Infect Immun* 60: 4932-4937, 1992
 8. Sismey-Durrant H.J. and Hopps R.M.: Effect of lipopolysaccharide from *Porphyromonas gingivalis* on prostaglandin E₂ and interleukin-1 β release from rat periosteal and human gingival fibroblasts *in vitro*. *Oral Microbiol Immunol* 6:378-380, 1991
 9. Wang P L. and Ohura K. *Porphyromonas gingivalis* lipopolysaccharide signaling in gingival fibroblasts-CD14 and Toll-like receptors. *Crit Rev Oral Biol Med* 13:132-142, 2002
 10. Kaufmann A, Gemsa D and Sprenger H. Differential desensitization of lipopolysaccharide-inducible chemokine gene expression in human monocytes and macrophages. *Eur J Immunol* 30:1562-1567, 2000
 11. Medvedev A E, Lentschat A, Wahl L M, Golenbock D T and Vogel S N. Dysregulation of LPS-induced Toll-like receptor 4-MyD88 complex formation and IL-1 receptor-associated kinase 1 activation in endotoxin-tolerant cells. *J Immunol* 169:5209-5216, 2002
 12. Martin M, Katz J, Vogel S N and Michalek S M. Differential induction of endotoxin tolerance by lipopolysaccharides derived from *Porphyromonas gingivalis* and *Escherichia coli*. *J Immunol* 167: 5278-5285, 2001
 13. Moreno C, Merino J, Vázquez B, Ramírez N, Echeverría A, Pastor F and Sánchez-Ibarrola A. Anti-inflammatory cytokines induce lipopolysaccharide tolerance in human monocytes without modifying toll-like receptor 4 membrane expression. *Scand J Immunol* 59: 553-558, 2004
 14. Medvedev A E, Kopydlowski K M. and Vogel S N. Inhibition of lipopolysaccharide-induced signal transduction in endotoxin-tolerized mouse macrophages. dysregulation of cytokine, chemokine, and toll-like receptor 2 and 4 gene expression. *J Immunol* 164:5564-5574, 2000
 15. Sato S, Nomura F, Kawai T, Takeuchi O, Mühlradt P, Takeda K and Akira S. Synergy and cross-tolerance between toll-like receptor (TLR) 2- and TLR4-mediated signaling pathways. *J Immunol* 165:7096-7101, 2000
 16. Matic M and Simon S R. Effects of gamma interferon on release of tumor necrosis factor alpha from lipopolysaccharide-tolerant human monocyte-derived macrophages. *Infect Immun* 60:3756-3762, 1992
 17. Ara T, Kurata K, Hirai K, Uchihashi T, Uematsu T, Imamura Y, Furusawa K, Kurihara S and Wang P L. Human gingival fibroblasts are critical in sustaining inflammation in periodontal disease. *J Periodontal Res* (in press), 2007
 18. Wang P L, Sato K, Oido M, Fujii T, Kowashi Y, Shinohara M, Ohura K, Tani H and Kuboki Y. Involvement of CD14 on human gingival fibroblasts in *Porphyromonas gingivalis* lipopolysaccharide-mediated interleukin-6 secretion. *Arch Oral Biol* 43:687-694, 1998
 19. Wang P L, Sato K, Oido M, Fujii T, Kowashi Y, Shinohara M, Ohura K, Tani H. and Kuboki Y. *Porphyromonas gingivalis* protease degrades cell adhesion molecules of human gingival fibroblasts. *J Hard Tissue Biol* 8:1-5, 1999
 20. Nomura F, Akashi S, Sakao Y, Sato S, Kawai T, Matsumoto M, Nakanishi K, Kimoto M, Miyake K, Takeda K and Akira S. Cutting edge: endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface toll-like receptor 4 expression. *J Immunol* 164:3476-3479, 2000
 21. Kinjyo I, Hanada T, Inagaki-Ohara K, Mori H, Aki D, Ohishi M, Yoshida H, Kubo M and Yoshimura A. SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. *Immunity* 17:583-591, 2002
 22. Nakagawa R, Naka T, Tsutsui H, Fujimoto M, Kimura A, Abe T, Seki E, Sato S, Takeuchi O, Takeda K, Akira S, Yamanishi K, Kawase I, Nakanishi K and Kishimoto T. SOCS-1 participates in negative regulation of LPS responses. *Immunity* 17:677-687, 2002
 23. Kobayashi K, Hernandez LD, Galán JE, Janeway C A Jr, Medzhitov R and Flavell RA. IRAK-M is a negative regulator of Toll-like receptor signaling. *Cell* 110:191-202,2002
 24. Sly L M, Rauh M J, Kalesnikoff J, Song C H. and Krystal G. LPS-induced upregulation of SHIP is essential for endotoxin tolerance. *Immunity* 21:227-239, 2004
 25. Fan H and Cook J A. Molecular mechanisms of endotoxin tolerance. *J Endotoxin Res* 10:71-84, 2004
 26. Neff L, Zeisel M, Sibilica J, Scholler-Guinard M, Klein J P and Wachsmann D. NF- κ B and the MAP kinases/AP-1 pathways are both involved in interleukin-6 and interleukin-8 expression in fibroblast-like synoviocytes stimulated by protein I/II, a modulin from oral streptococci. *Cell Microbiol*

- 3: 703-712, 2001
27. Cho Y H, Lee C H and Kim S G. Potentiation of lipopolysaccharide-inducible cyclooxygenase 2 expression by C2-ceramide via c-Jun N-terminal kinase-mediated activation of CCAAT/enhancer binding protein β in macrophages. *Mol Pharmacol* 63:512-523, 2003
28. Wang P L, Oido-Mori M, Fujii T, Kowashi Y, Kikuchi M, Suetsugu Y, Tanaka J, Azuma Y, Shinohara M and Ohura K. Heterogeneous expression of Toll-like receptor 4 and downregulation of Toll-like receptor 4 expression on human gingival fibroblasts by *Porphyromonas gingivalis* lipopolysaccharide. *Biochem Biophys Res Commun* 288:863-867, 2001